---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-059551"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:38:45.596377+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents

## Summary
- Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.
- Ruling affirms December 2023 District of New Jersey verdict; Corcept will consider further judicial review.
- CEO Joseph Belanoff expressed disappointment and said company will vigorously defend its rights.
- Patents cover methods used in treating Cushing's syndrome; generic entry would weaken Korlym's market exclusivity.

## SEC filing metadata
- accession: 0001193125-26-059551
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312526059551/0001193125-26-059551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312526059551/d25779d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-059551
- JSON: https://secwatch.observer/filing/0001193125-26-059551.json
- Plain text: https://secwatch.observer/filing/0001193125-26-059551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.